NEWTOWN | Jotup

Helius Medical Technologies, Inc. Receives UPC Numbers for its PoNS® System and Mouthpiece

Retrieved on:

Thursday, September 28, 2023

Management of multiple sclerosis, Helios, CMS, GTIN, Pons, HSDT, UPC, Prescription, Pharmacy, Medicare, PBM, Durable medical equipment, Global Trade Item Number, HCPCS, Wolters Kluwer, GameChanger, Health care

NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that its Portable Neuromodulation Stimulator (“PoNS®”) system and mouthpiece have been assigned universal product code (“UPC”) numbers by Wolters Kluwer Health – Medi-Span® (“Medi-Span”). Medi-Span is the leading automated clinical screening solution– providing a data backbone and vital support to payers, pharmacy benefit managers (“PBMs”), wholesalers, and manufacturers.

Key Points:

The PoNS system has been assigned the Global Trade Item Number (“GTIN”) of 00864288000462, with a direct price of $25,700.
Consequently, this will allow Helius to pursue reimbursement through both the pharmacy and the Durable Medical Equipment (“DME”)/HCPCS pathways.
“Receiving UPC numbers for the PoNS system and mouthpiece is a gamechanger for Helius,” said Dane Andreeff, Helius’ President and Chief Executive Officer.
"We will now be able to reference these UPC numbers as we negotiate reimbursement with third party payers, and prescriptions can be written with these UPC numbers.

LUMN INVESTOR ALERT: Edelson Lechtzin LLP Urges Lumen Technologies, Inc. (NYSE: LUMN) Shareholders with Substantial Losses to Consult Legal Counsel About the Pending Securities Fraud Class Action

Retrieved on:

Friday, September 22, 2023

Please contact Edelson Lechtzin LLP at 844-696-7492 to discuss your investment losses, or by e-mail at [email protected] .

Key Points:

Please contact Edelson Lechtzin LLP at 844-696-7492 to discuss your investment losses, or by e-mail at [email protected] .
A copy of the class action complaint can be viewed HERE .
Based in Monroe, Louisiana, Lumen Technologies, Inc. provides telecommunications, network services, security, cloud solutions, voice, and managed services.
On this news, Lumen’s stock price fell $0.15 per share, or 8.11%, to close at $1.70 per share on July 17, 2023.

Helius to Bring its Innovative PoNS Therapy for Improvement of Gait in People with MS, to the 2023 Academy of Neurologic Physical Therapy Conference

Retrieved on:

Thursday, September 21, 2023

NEWTOWN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it will exhibit at the Academy of Neurologic Physical Therapy 2023 Annual Conference, September 28-30 at the Hyatt Regency Minneapolis, marking its first appearance at the conference.

Key Points:

The Company’s focus at booth 7 will be its innovative Portable Neuromodulation Stimulator (PoNS®), an orally applied therapy delivered by translingual neurostimulation to improve gait deficit in people with multiple sclerosis (“MS”) .
Helius’ debut at the conference is timely, coming just after National Rehabilitation Awareness Week (Sept. 18-24) and on the eve of National Physical Therapy Month (October).
An individualized physical therapy regimen performed with the PoNS device, mostly in clinic for the first two weeks then at home for twelve additional weeks, is the hallmark of PoNS Therapy™.
When used regularly and consistently over the 14-week treatment period, PoNS triggers neuroplastic mechanisms that can lead to significant improvement in gait function .

University of Montreal’s School of Rehabilitation to Purchase Ten PoNS® Devices for Research Study on Stroke Recovery

Retrieved on:

Wednesday, September 20, 2023

Helios, Gait, Pons, HSDT, Stroke, Research, Rehabilitation, Patient, Risk, School, United, Falling, Pharmaceutical industry

NEWTOWN, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has signed an agreement with the School of Rehabilitation at the Université de Montréal (“UdeM”) for the purchase of ten PoNS devices to be used in a research project linked to stroke recovery.

Key Points:

NEWTOWN, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has signed an agreement with the School of Rehabilitation at the Université de Montréal (“UdeM”) for the purchase of ten PoNS devices to be used in a research project linked to stroke recovery.
“We are excited to work with UdeM’s School of Rehabilitation to explore further the benefits of using PoNS Therapy during a stroke patient’s recovery journey.
Since March 2023, PoNS has been authorized in Canada to treat gait deficit due to mild and moderate symptoms from stroke, and the body of clinical evidence shows that patients treated with PoNS experience significant improvement in gait and a reduced risk of falling,” said Antonella Favit-Van Pelt, M.D., Ph.D., Helius' Chief Medical Officer.
“UdeM’s study will provide Helius important information about how PoNS Therapy can be best utilized to help those suffering from stroke and will also serve as another step forward in pursuing market access for stroke in the United States.”

Edelson Lechtzin LLP is Investigating Securities Fraud Claims on Behalf of Faze Holdings Inc. (Nasdaq: FAZE) Shareholders Who Held B. Riley Principal 150 Merger Corp. (Nasdaq: BRPM) Shares Prior to the Merger

Retrieved on:

Friday, September 15, 2023

LLP, FaZe Clan, Acquisition, Special, John B. Riley, Fraud, Security (finance)

NEWTOWN, Pa., Sept. 15, 2023 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating securities fraud and breach of fiduciary duty claims on behalf of former shareholders of B. Riley Principal 150 Merger Corp. (“B.

Key Points:

NEWTOWN, Pa., Sept. 15, 2023 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating securities fraud and breach of fiduciary duty claims on behalf of former shareholders of B. Riley Principal 150 Merger Corp. (“B.
Riley”) (Nasdaq: BRPM), a special purpose acquisition company (“SPAC”), who acquired BRPM shares before the closing of its business combination with Faze Holdings Inc. (“FaZe”) (Nasdaq: FAZE), on or before July 20, 2022.
The business combination of B. Riley and FaZe was approved by B. Riley shareholders at its Special Meeting held on July 15, 2022.
FaZe common stock began trading on the Nasdaq under its new ticker symbol “FAZE”, on July 20, 2022.

INVESTOR ALERT: Edelson Lechtzin LLP Reminds Discover Financial Services (NYSE: DFS) Shareholders to Consider Seeking Counsel before the October 31 Lead Plaintiff Deadline

Retrieved on:

Wednesday, September 13, 2023

LLP, File, Share repurchase, Risk management, DFS, HERE, Class Action, District court, Discover Financial, Douglas v. U.S. District Court ex rel Talk America, News, NYSE, Discover Card, Cryptocurrency, Bank

NEWTOWN, Pa., Sept. 12, 2023 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating securities fraud claims on behalf of all purchasers and holders of Discover Financial Services.

Key Points:

NEWTOWN, Pa., Sept. 12, 2023 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating securities fraud claims on behalf of all purchasers and holders of Discover Financial Services.
(NYSE: DFS) common stock between February 21, 2019 and August 14, 2023, both dates inclusive (the “Class Period”).
Investors who purchased DFS common stock may move the U.S. District Court for the Northern District of Illinois to appoint them as lead plaintiff, no later than October 31, 2023.
Please contact Edelson Lechtzin LLP at 844-696-7492 to discuss your investment losses, or by e-mail at [email protected] .

INVESTOR ALERT: Edelson Lechtzin LLP Reminds NAPCO Security Technologies, Inc. (NASDAQ: NSSC) Shareholders to Consider Seeking Counsel before the October 30th Lead Plaintiff Deadline

Retrieved on:

Wednesday, September 13, 2023

LLP, COGS, Bank statement, HERE, NAPCO, District court, NSSC, Complaint, Douglas v. U.S. District Court ex rel Talk America, News, Cryptocurrency

Investors who purchased NAPCO common stock may move the U.S. District Court for the Eastern District of New York to appoint them as lead plaintiff, no later than October 30, 2023.

Key Points:

Investors who purchased NAPCO common stock may move the U.S. District Court for the Eastern District of New York to appoint them as lead plaintiff, no later than October 30, 2023.
Please contact Edelson Lechtzin LLP at 844-696-7492 to discuss your investment losses, or by e-mail at [email protected] .
Background on NAPCO Security Technologies, Inc.
NAPCO Security Technologies, Inc., established in 1969, creates and distributes electronic security products worldwide.
Headquartered in Amityville, New York, NAPCO specializes in supplying its products to independent security equipment distributors, dealers, and installers.

Helius Medical Technologies to Present at the 2023 Interdisciplinary Association of Functional Neuroscience and Rehabilitation Conference

Retrieved on:

Wednesday, September 13, 2023

Management of multiple sclerosis, Health, Gait, Pons, HSDT, Stroke, Therapy, Interdisciplinary Association for Population Health Science, Rehabilitation, Multiple sclerosis, Movement, Science, Neuroscience, Patient, Person-centered therapy, Conference, Nursing

NEWTOWN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Antonella Favit-Van Pelt, M.D., Ph.D., Helius’ Chief Medical Officer, will present at the Interdisciplinary Association of Neuroscience and Rehabilitation (IAFNR) Conference from September 28 to October 1, 2023. The IAFNR Conference is a four-day virtual event intended for neuroscience experts, including movement and neuromuscular disorder specialists, physical therapists, and occupational therapists.

Key Points:

-- Presentation to educate on Portable Neuromodulation Stimulator (PoNS®) Therapy, highlighting the differentiation from other neuromodulation technologies, and the science behind its effectiveness, clinical data, safety profile --
NEWTOWN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Antonella Favit-Van Pelt, M.D., Ph.D., Helius’ Chief Medical Officer, will present at the Interdisciplinary Association of Neuroscience and Rehabilitation ( IAFNR ) Conference from September 28 to October 1, 2023.
The IAFNR Conference is a four-day virtual event intended for neuroscience experts, including movement and neuromuscular disorder specialists, physical therapists, and occupational therapists.
“The field of neuromodulation-based healthcare is evolving rapidly, and we believe that PoNS Therapy™ is a groundbreaking treatment for people suffering from balance or gait impairment.
Our goal has always been to bring this impactful technology to as many qualifying patients as possible, and this forum is an excellent platform to create awareness and engage leading practitioners in neurorehabilitation.”
Details of the presentation are as follows:

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on:

Wednesday, September 6, 2023

Cancer, Therapy, Patient, Conference, Corporation, Pharmaceutical industry

NEWTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

Key Points:

NEWTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.
The Onconova Management Team will be available for 1X1 meetings during the conference.
Those interested in requesting a meeting should contact their H.C. Wainwright representative.
The presentation can be viewed here or on the “ Corporate Events and Presentations ” section of the Onconova website and will be archived for 90 days.

Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria

Retrieved on:

Tuesday, September 5, 2023

HSDT, Helios, Cryptocurrency, Property management

NEWTOWN, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on August 31, 2023, Helius received formal notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC indicating that Helius has evidenced full compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market.

Key Points:

NEWTOWN, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on August 31, 2023, Helius received formal notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC indicating that Helius has evidenced full compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market.
As a result, the listing matter has been closed.